Immunitybio Inc
NASDAQ:IBRX
Intrinsic Value
ImmunityBio, Inc. is a clinical stage immunotherapy company. [ Read More ]
The intrinsic value of one IBRX stock under the Base Case scenario is 15.37 USD. Compared to the current market price of 5.11 USD, Immunitybio Inc is Undervalued by 67%.
Valuation Backtest
Immunitybio Inc
Run backtest to discover the historical profit from buying and selling IBRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Immunitybio Inc
Current Assets | 294.1m |
Cash & Short-Term Investments | 266.5m |
Receivables | 3.2m |
Other Current Assets | 24.5m |
Non-Current Assets | 210.4m |
Long-Term Investments | 891k |
PP&E | 182.7m |
Intangibles | 17.1m |
Other Non-Current Assets | 9.7m |
Current Liabilities | 58.3m |
Accounts Payable | 9.2m |
Accrued Liabilities | 46.5m |
Other Current Liabilities | 2.6m |
Non-Current Liabilities | 1B |
Long-Term Debt | 837m |
Other Non-Current Liabilities | 196.2m |
Earnings Waterfall
Immunitybio Inc
Revenue
|
622k
USD
|
Operating Expenses
|
-362m
USD
|
Operating Income
|
-361.4m
USD
|
Other Expenses
|
-221.8m
USD
|
Net Income
|
-583.2m
USD
|
Free Cash Flow Analysis
Immunitybio Inc
IBRX Profitability Score
Profitability Due Diligence
Immunitybio Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Immunitybio Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
IBRX Solvency Score
Solvency Due Diligence
Immunitybio Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Immunitybio Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IBRX Price Targets Summary
Immunitybio Inc
According to Wall Street analysts, the average 1-year price target for IBRX is 5.1 USD with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Ownership
IBRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IBRX Price
Immunitybio Inc
Average Annual Return | -54.28% |
Standard Deviation of Annual Returns | 24.93% |
Max Drawdown | -97% |
Market Capitalization | 3.4B USD |
Shares Outstanding | 670 331 008 |
Percentage of Shares Shorted | 38.97% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2015-07-28. The firm is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its immunotherapy and cell therapy platforms include antibody cytokine fusion proteins; synthetic immunomodulators; vaccine technologies, which includes human adenovirus (hAd5) viral vector, and genetically modified off-the-shelf natural killer cells (NK cells), which activate both the innate (NK cell and macrophage) and adaptive (T cell) immune systems. Its lead cytokine fusion protein, Anktiva, is an interleukin-15 (IL-15) superagonist complex. Its clinical pipeline consists of approximately 26 actively recruiting clinical trials of which 17 are in Phase II or III development, across 13 indications in liquid and solid tumors, including bladder, pancreatic, and lung cancers, and infectious diseases, including SARS-CoV-2 and human immunodeficiency virus (HIV).
Contact
IPO
Employees
Officers
The intrinsic value of one IBRX stock under the Base Case scenario is 15.37 USD.
Compared to the current market price of 5.11 USD, Immunitybio Inc is Undervalued by 67%.